Physician profile
Casey L Wegener
NPI 1902293004
$2,520.69
in general payments reported to CMS, 2019-2025
19 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $39.57 · 2024: $1,127 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.81 |
| Education | $350.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.99 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $383.77 | 2024-2025 | |
| Janssen Biotech, INC. | $337.86 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $258.55 | 2024-2025 | |
| Incyte Corporation | $193.11 | 2024-2025 | Opzelura |
| Amgen INC. | $154.20 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $143.57 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $142.76 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Pfizer INC. | $114.28 | 2024-2025 | |
| Genzyme Corporation | $81.23 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $62.55 | 2024-2025 | |
| Dermavant Sciences, INC. | $58.77 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $52.35 | 2024-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $32.71 | 2025 | Zoryve |
| Almirall LLC | $30.77 | 2025 | Klisyri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $23.83 | 2024 | |
| Botanix Sb INC | $20.73 | 2025 | Sofdra |
| Biofrontera INC. | $18.91 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $12.75 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Wegener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.